NEW ENGLAND GYNECOLOGY PLLC
Publications &
Presentations
A record of peer-reviewed scholarship, international presentations, and invited lectures spanning gynecologic oncology, translational science, cancer prevention, and reproductive medicine — spanning more than 15 years of active investigation.
13
PEER-REVIEWED PUBLICATIONS
20
PUBLISHED ARTIFACTS
31+
PRESENTATIONS & LECTURES
3
AD-HOC REVIEWER JOURNALS
REPORTS OF ORIGINAL WORK · CASE REPORTS · REVIEW ARTICLES
Peer-Reviewed
Publications
Citation source: Google Scholar. Impact factor source: respective journal websites.
LANDMARK CONTRIBUTIONS
- Three publications form the core scientific arc: OPAL Trial (2024) · OVARIO Phase II (2022) · Cisplatin Resistance & Oxidative Stress (2014)
ORIGINAL RESEARCH
2024 · LANDMARK
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J, Felicetti B, Baines AJ, YoussefAgha A, Rojas-Espaillat L, Ortiz AG, Provencher D, Vázquez RM, Cortijo LG, Zeng X.
Trials. 2024 May 4;25(1):301.
2022 · LANDMARK
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab (NCT03326193).
Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton EK, Wang P, Gupta D, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL.
Gynecologic Oncology. 2022 Jun 8; S0090-8258(22)00331-6.
ORIGINAL RESEARCH · 2017
Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
Fletcher NM, Belotte J, Saed MG, Memaj I, Diamond MP, Morris RT, Saed GM.
Free Radical Biology and Medicine. 2017 Jan;102:122–132.
- Role: Design, Data Analysis, Manuscript Writing
ORIGINAL RESEARCH · 2016
The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer.
Nusrat O, Belotte J, Fletcher NM, Memaj I, Saed MG, Diamond MP, Saed GM.
Reproductive Sciences. 2016 Apr 26. pii: 1933719116645191.
- Role: Study Conception, Design, Data Analysis, Manuscript Writing
ORIGINAL RESEARCH · 2015
A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival.
Belotte J, Fletcher NM, Saed MG, Abusamaan MS, Dyson G, Diamond MP, Saed GM.
PLOS ONE. 2015 Aug 24;10(8):e0135739.
ORIGINAL RESEARCH · 2015
Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer.
Belotte J, Fletcher NM, Alexis M, Morris RT, Munkarah AR, Diamond MP, Saed GM.
Reproductive Sciences. 2015 Jan;22(1):38–46.
2014 · LANDMARK
The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer.
Belotte J, Fletcher NM, Awonuga AO, Alexis M, Abu-Soud HM, Saed MG, Diamond MP, Saed GM.
Reproductive Sciences. 2014 Apr;21(4):503–8.
ORIGINAL RESEARCH · 2012
Myeloperoxidase and free iron levels: potential biomarkers for early detection and prognosis of ovarian cancer.
Fletcher NM, Jiang Z, Ali-Fehmi R, Levin NK, Belotte J, Tainsky MA, Diamond MP, Abu-Soud HM, Saed GM.
Cancer Biomarkers. 2012;10(6):267–75.
- Role: Study Conception, Design, Data Analysis, Manuscript Writing
CASE REPORTS
CASE REPORT · 2014
Successful laparoscopic management of ruptured tubal pregnancy with an ipsilateral ectopic pelvic kidney.
Belotte J, Belotte J, Alexis M, Awonuga AO, Aguin TJ.
Case Reports in Obstetrics and Gynecology. 2014;2014:682737.
CASE REPORT · 2012
Platinum-based combination chemotherapy for the treatment of advanced-stage squamous cell carcinoma of the vulva.
Belotte J, Awonuga AO, Bolinjkar R, Alexis M, Tabassum F, Deppe G.
Obstetrics & Gynecology. 2012 Aug;120(2 Pt 2):458–60.
CASE REPORTS
REVIEW · 2014
Successful laparoscopic management of ruptured tubal pregnancy with an ipsilateral ectopic pelvic kidney.
Awonuga AO, Belotte J, Abuanzeh S, Fletcher NM, Diamond MP, Saed GM.
Reproductive Sciences. 2014 Feb;21(7):823–836.
Ready to Build a
Smarter Learning Program?
Whether you are a residency program director, a health system executive, a research institution, or an organization committed to women’s health — NEG+ will design an education program that moves your team forward.